Overview
The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment Center.
The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD, following the provision of a recombinant drug in France; It will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.
Eligibility
Inclusion Criteria:
- Constitutional Von Willebrand Disease patient, of any severity, with or without Von Willebrand Factors inhibitors
- Patient included in the research database BERHLINGO
- Patient treated or not by desmopressin or Von Willebrand Factor/FVIII/by-passing agents available on the French market (at baseline)
- Patient who agrees to participate in the HOPSCOTcH-Will II and followed in one of the 5 investigator centers
Exclusion Criteria:
- Patients under guardianship